Bariatric Surgery and Risk of End-Stage Liver Disease in a Four-Country Cohort Study

• DOI: 10.1007/s11695-025-07857-x
• Publication Date: 2025-04-12T11:23:11Z
• Authors: Dag Holmberg; Giola Santoni; My von Euler-Chelpin; Joonas H. Kauppila; Eivind Ness-Jensen; Jesper Lagergren
• Keywords: Liver disease

Metabolic dysfunction-associated steatotic liver disease can progress to end-stage disease. Whether bariatric surgery influences this risk is uncertain. This population-based cohort study included all patients with an obesity diagnosis between 1989 and 2020 according the nationwide patient registries in Denmark, Finland, Norway, Sweden. Bariatric was compared non-operative care for incidence mortality Patients a history of alcohol overconsumption or at baseline were excluded. Multivariable Cox regression provided hazard ratios (HR) 95% confidence intervals (CI), adjusted sex, calendar year, diabetes, Charlson comorbidity index, country. Among 654,409 participants obesity, 86,356 (12.6%) underwent surgery. During follow-up period up 31 years (median 7.3 years), followed by increased (HR 1.23, CI 1.11-1.37) 1.93, 1.56-2.38) care. The decreased 1 5 after but thereafter increased. Censoring who developed specific diseases (not disease) during canceled association 0.92, 0.70-1.06). similar within 1-5 follow-up, more than twofold Analyses restricted gastric bypass showed associations regarding both 1.26, 1.11-1.43) 2.20, 1.72-2.82) might be